Countdown to Conference
Days
Hours
Min
Sec
 

PRESS

ILD and IPF Programs

HomeProgramBrowse Programs and Exhibits by Topic ▶ ILD and IPF Programs

Interstitial Lung Disease &
Idiopathic Pulmonary Fibrosis Programs

The following programs are related to Interstitial Lung Disease and Idiopathic Pulmonary Fibrosis Programs and are available on-demand through Friday, July 2.


Clinical and Scientific Sessions


The Clinical and Scientific Sessions and abstracts accepted for the program will be presented virtually through our online platform. Starting May 13, attendees can access on-demand content. The sessions listed with a date and time below will have a live component where you may pose questions to the speakers. All content will continue to be available on-demand through July 2.

Mini Symposia and Thematic Poster Sessions are abstract based sessions.

Browse all clinical and scientific sessions →

Session Title Session Type Join Us!
D011 CONUNDRUMS AND CONTROVERSIES IN DIAGNOSIS AND MANAGEMENT OF INTERSTITIAL LUNG DISEASE: PRO/CON DEBATES Scientifc Symposium 3:30 - 5 p.m. EDT, Wednesday, May 19
D021 CLINICAL YEAR IN REVIEW 4
•  Health Disparities in PCCSM
•  Interstitial Lung Disease
•  Asthma
•  Pulmonary Rehabilitation
Scientific Symposium On-Demand
Hot Topic sessions recommended by the International Conference Committee (ICC).

 

Industry Programs


Enhance your educational experience during ATS 2021 by listening to industry experts discuss the latest information on products/services or disease awareness related to pulmonary, critical care, and sleep medicine.

There are 24 programs from Sunday, May 16 – Wednesday, May 19 with a total of six programs each day – three programs from 12-1 p.m. ET and three programs from 5:30-6:30 p.m. ET.

Don’t miss programs that are live and only accessible during their program time! Some programs will be available on-demand shortly after their program time through the end of the virtual conference, July 2.

Browse all industry programs →


The Role of OFEV® (nintedanib) capsules: Insights for the Health Care Practitioner


Sponsored by Boehringer Ingelheim Pharmaceuticals, Inc.
Live
Monday, May 17, 5:30 - 6:30 p.m. EDT | Open to all attendees
Topic: ILD

Add to My Calendar

Join Dr. Steven Nathan and Dr. Firas Kassab as they provide an overview of the OFEV pivotal safety and efficacy data and provide case study examples to underscore the importance of identifying appropriate patients for treatment with OFEV. This presentation is made on behalf of Boehringer Ingelheim Pharmaceuticals, Inc.

Speakers:

  • Steven D. Nathan, MD, FCCP, Medical Director, Advanced Lung Disease, Lung Transplant & Inova Lung Services, Inova Fairfax Hospital, Falls Church, VA
  • Firas Kassab, MD, FACR, Rheumatologist, Articularis Healthcare Group, South Charlotte-Rheumatology, Charlotte, NC



Identifying Autoimmune Interstitial Lung Diseases: A Rheumatologist’s Perspective


Sponsored by Boehringer Ingelheim Pharmaceuticals, Inc.
On-demand
Tuesday, May 18, 12 - 12:30 p.m. EDT | Open to all attendees
Topic: ILD

Add to My Calendar

Join expert rheumatologist Dr. Richard Silver as he discusses identifying autoimmune interstitial lung diseases, reviews patient case studies, and discusses the importance of early disease recognition. This presentation is sponsored by Boehringer Ingelheim Pharmaceuticals, Inc.

Speakers:

  • Richard Silver, MD, Professor of Medicine and Pediatrics, Vice Chair, Development, Division of Rheumatology and Immunology, Medical University of South Carolina, Charleston, SC



Utility of Envisia Genomic Classifier in Multi-Disciplinary ILD Management


Sponsored by Veracyte
Live and available on-demand
Tuesday, May 18, 5:30 - 6:30 p.m. EDT | Open to all attendees
Topic: ILD

Add to My Calendar

In this multi-disciplinary (MDD) discussion, ILD experts will review a range of cases from the Envisia BRAVE sample collection study and discuss the role of the Envisia genomic classifier in the diagnosis and prognosis of ILD patients in clinical practice.

Speakers:

  • Lisa H. Lancaster, MD, Professor of Medicine Division of Allergy, Pulmonary and Critical Care Medicine, Medical Director ILD Program, Vanderbilt University Medical Center
  • David A. Lynch, MB, Professor of Radiology, National Jewish Health
  • Thomas V. Colby, MD, Emeritus Professor of Laboratory Medicine and Pathology, Mayo Clinic



An Animated Exploration of Chronic Fibrosing Interstitial Lung Disease: From Diagnosis to Management in the Era of Antifibrotic Therapy


This non-CME educational program is sponsored by PVI, PeerView Institute for Medical Education and supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.
On-demand
Wednesday, May 19, 12 - 1 p.m. EDT | Open to all attendees
Topic: ILD

Add to My Calendar

Pulmonology experts will discuss the latest clinical efficacy and safety data for novel and emerging therapies for CF-ILD. The discussion will be supplemented with animated video and infographics.

Speakers:

  • Kevin R. Flaherty, MD, MS, Professor of Medicine, Co-Director, Interstitial Lung Disease Destination Clinic, University of Michigan
  • Erica L. Herzog, MD, PhD, Professor of Medicine and Pathology, Associate Dean, Medical Student Research, Yale School of Medicine
  • Lisa H. Lancaster, MD, Professor of Medicine, Director, Interstitial Lung Disease Program, Division of Allergy, Pulmonary, and Critical Care Medicine, Vanderbilt University Medical Center



Improving Prognosis in SSc-ILD: Best Practices in Diagnosis, Optimizing Clinical Management, and Efficient Patient Communication


This non-CME educational program is sponsored by Physician's Educational Resource and supported by a grant from Boehringer Ingelheim Pharmaceuticals, Inc.
Live
Wednesday, May 19, 5:30 - 6:30 p.m. EDT | Open to all attendees
Topic: SSc-ILD

Add to My Calendar

Interstitial lung disease (ILD) is a frequent and debilitating complication of systemic sclerosis (SSc) with a complex pathophysiology. Up to 90% of the 50,000 individuals in the United States diagnosed with SSc will develop some degree of ILD, determining both disease severity and prognosis. SSc-ILD is characterized by systemic inflammation, progressive scarring of the lungs, and eventual respiratory failure. Until recently, there were no approved therapies but now patients with SSc-ILD may benefit from early intervention to prevent disease progression.

A panel of experts will first review the classification and pathophysiology of SSc-ILD and then share insights for initial pulmonary assessment. Patient cases will be used to identify predictors of disease progression and considerations for initiation of therapy with best approaches for shared decision-making in discussing patient expectations.

Speakers:

  • Steven D. Nathan, MD, Medical Director, Advanced Lung Disease and Transplant Program, Inova Fairfax Hospital
  • Kristin B. Highland, MD, MSCR, Director, Rheumatic Lung Disease Program, Cleveland Clinic
  • Justin Oldham, MD MS, Associate Professor of Medicine
    Autoimmune Lung Center and Interstitial Lung Disease Program, University of California at Davis
  • Joshua Solomon, MD, Associate Professor of Medicine, National Jewish Health



IPF Disease Challenge


This non-CME educational program is sponsored by the France Foundation and supported by a grant from Boehringer Ingelheim Pharmaceuticals, Inc.
Live and available on-demand
Wednesday, May 19, 5:30 - 6:30 p.m. EDT | Open to all attendees
Topic: IPF

Add to My Calendar

Are you up for the IPF Disease Challenge? Game on!
Unwind after a long day with a Kahoot!

This is NOT an old-school didactic lecture! Discover better ways to manage your patients with IPF while engaging in some “friendly competition.” Gaming elements will answer questions such as:

  • How do I integrate new IPF treatment info into practice?
  • When and why would I start antifibrotic therapy?
  • Should I stop or switch treatment?
  • How do I emphasize to patients that treatment adherence impacts disease progression?

Hosted by Kevin Flaherty, MD, from the University of Michigan and Lisa H. Lancaster, MD, from Vanderbilt University.

Supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Speakers:

  • Lisa H. Lancaster, MD, Medical Director Interstitial Lung Disease Program, Professor of Medicine, Vanderbilt University
  • Kevin Robert Flaherty, MD, Director of the Michigan Medicine Interstitial Lung Disease Program, Professor of Medicine, University of Michigan

Exhibitors


The ATS 2021 Virtual Exhibits in the Industry Solutions Center offer the latest innovations and newest advances in pulmonary, critical care and sleep medicine. Stop by these exhibitors to learn more about the latest in Interstitial Lung Disease & Idiopathic Pulmonary Fibrosis Programs:

  • 4DMedical
  • Asian Pacific Society of Respirology (APSR)
  • Bayer
  • Biodesix, Inc.
  • Boehringer Ingelheim Pharmaceuticals, Inc.
  • Data Sciences Internatonal (DSI)
  • Canadian Thoracic Society
  • ECO MEDICS - ECO PHYSICS
  • European Respiratory Society
  • Fidelta Ltd.
  • FUJIFILM Medical Systems U.S.A., Inc.
  • Genentech
  • Hermansky-Pudlak Syndrome
  • MDPI
  • MGC Diagnostics
  • Owlstone Medical
  • National Heart, Lung, and Blood Institute
  • Polarean
  • Pulmonary Fibrosis Foundation
  • Scleroderma Foundation
  • Sociedad Mexicana De Neumología Y Cirugía De Tórax
  • STEMCELL Technologies
  • Thirona


You can also access:


  • Abstract Presentations
  • Networking Opportunities
  • MOC points and CME Credit
  • Q & A and Chat With Speakers and Authors
  • San Diego Sleuth Challenge
  • Wellness Activities